Related Experiment Videos

Ca(2+)/calmodulin-dependent protein kinase IV expression in epithelial ovarian cancer

Noriyuki Takai1, Tami Miyazaki, Masakazu Nishida

  • 1Department of Obstetrics and Gynecology, Oita Medical University, 879-5593, Oita, Japan. takai@oita-med.ac.jp

Cancer Letters
|June 18, 2002
PubMed

Insights

Calcium/calmodulin-dependent protein kinase IV (CaMKIV) is elevated in ovarian cancer, correlating with poor prognosis. This protein kinase

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ca(2+)/calmodulin-dependent protein kinase IV (CaMKIV) is a key regulator of gene expression and cell proliferation.
  • CaMKIV's role in cell cycle progression suggests potential involvement in carcinogenesis.
  • Enhanced CaMKIV expression is observed in other cancer types, including lung and liver carcinomas.

Purpose of the Study:

  • To investigate the expression and clinical significance of CaMKIV in epithelial ovarian carcinogenesis.
  • To determine the correlation between CaMKIV expression levels and clinicopathological features of ovarian cancer.
  • To assess the prognostic value of CaMKIV in patients with epithelial ovarian cancer.

Main Methods:

  • Fluorescent immunohistochemistry was used to analyze CaMKIV protein expression in ovarian tissues.
  • Samples included 26 patients with epithelial ovarian carcinoma and 10 with benign cystadenoma.
  • Statistical analysis, including univariate Cox regression, was performed to correlate CaMKIV expression with patient characteristics and outcomes.

Main Results:

  • CaMKIV was not detected in benign ovarian cystadenoma tissues.
  • CaMKIV protein was predominantly localized in the nucleus of epithelial ovarian cancer cells.
  • CaMKIV expression significantly correlated with advanced clinical stage, higher histological grade, and poorer clinical outcome (P<0.01).

Conclusions:

  • CaMKIV expression is significantly associated with the malignant potential of epithelial ovarian cancer.
  • CaMKIV expression serves as a potential biomarker for poor prognosis in ovarian cancer patients.
  • Targeting CaMKIV may represent a therapeutic strategy for epithelial ovarian cancer.

Related Concept Videos